Cortez Drugs – FDA 483, Feb 7, 2020

This FDA Form 483 document details observations made during an inspection, indicating deficiencies in the firm's operations.

**Observation 1:** The firm failed to establish adequate procedures for the cleaning and maintenance of equipment. This suggests a lack of documented and implemented protocols to ensure equipment is properly cleaned and maintained, which is crucial for preventing cross-contamination and ensuring product quality.

**Observation 2:** The firm did not adequately validate the manufacturing process for Drug X. Process validation is a critical requirement to ensure that a manufacturing process consistently produces a product meeting its predetermined specifications and quality attributes. The absence of adequate validation indicates a potential risk of inconsistent product quality for Drug X.

**Observation 3:** The firm did not have proper controls in place to prevent contamination of products. This is a significant finding, as it implies a failure in the quality system to safeguard products from various sources of contamination (e.g., microbial, particulate, cross-contamination from other products). This deficiency poses a direct risk to product safety and efficacy.

Collectively, these observations highlight issues within the firm's quality system, specifically concerning equipment management, process control, and contamination prevention. These deficiencies could lead to significant business and operational implications, including potential regulatory actions, product recalls, and damage to reputation, due to the failure to meet Good Manufacturing Practice (GMP) requirements.